Non-muscle Invasive Bladder Urothelial Carcinoma
📧 Sign up to get email alerts when something new happens for Non-muscle Invasive Bladder Urothelial Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial [Phase 2]
Phase 2 trial evaluating whether adding pembrolizumab to radiation therapy improves outcomes for non-muscle invasive bladder urothelial carc…
-
CLINICAL_TRIALS trial_result · 2022-08-10Clinical Trial Update: Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable [Phase 2]
Phase 2 trial evaluating disitamab vedotin combined with tislelizumab for Her2-overexpressing high-risk non-muscle invasive bladder urotheli…
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study [Phase 2]
Phase 2 clinical trial evaluating tilelizumab in combination with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcin…
-
CLINICAL_TRIALS trial_result · 2021-10-29Clinical Trial Update: Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable [Phase 2]
Phase 2 clinical trial evaluating tilelizumab with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma that is not…